Shaperon Inc. (378800)
Market Closed
11 Aug, 06:30
KRX SM KRX SM Primary ₩
473. 00
+6
+1.2848%
₩
59.4B Market Cap
- P/E Ratio
- Div Yield
635,030 Volume
- Eps
₩ 467
Previous Close Want to track 378800 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
378800 closed today higher at ₩473, an increase of 1.2848% from yesterday's close, completing a monthly decrease of -9.387% or -₩49. Over the past 12 months, 378800 stock lost -72.956%.
378800 is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.
Shaperon Inc. (378800) FAQ
What is the stock price today?
The current price is ₩473.00.
On which exchange is it traded?
Shaperon Inc. is listed on KRX SM.
What is its stock symbol?
The ticker symbol is 378800.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 59.4B.
Has Shaperon Inc. ever had a stock split?
No, there has never been a stock split.
Shaperon Inc. Profile
| Biotechnology Industry | Healthcare Sector | Seung-Yong Seong M.D., Ph.D. CEO | KRX SM Exchange | - ISIN |
| KR Country | 50 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Shaperon Inc. is a clinical stage biotech company based in Seoul, South Korea, established in 2008. The enterprise is focused on the development of innovative inflammasome inhibitors aimed at immune-mediated inflammatory disorders which currently have high unmet medical needs. Alongside, it advances in nanobody therapeutics, leveraging cutting-edge technology to offer novel treatment solutions. With its commitment to addressing critical gaps in current medical treatments, Shaperon is at the forefront of biotechnological advancements in the field of immunology and inflammatory diseases.
Products and Services
- NuGel: A gel-type drug candidate for atopic dermatitis currently in Phase 2 clinical trials. Designed as a topical solution, it represents Shaperon's dedication to innovative treatment options for dermatological conditions.
- NuSepin: This is an IV injection form of HY209, also in Phase 2 clinical trials, aimed at the treatment of systemic inflammatory response syndrome (SIRS). It underscores the company's effort in addressing severe immune responses that can lead to critical conditions.
- Oral HY209: An oral formulation of HY209 in development for the treatment of neuroinflammatory diseases. This indicates Shaperon’s venture into creating more accessible options for patients suffering from neurological inflammation.
- HY209 Analogues: Focused on the treatment of chronic inflammation, these analogues of HY209 showcase the versatility and broad application potential of Shaperon’s proprietary compounds in various inflammatory conditions.
- Papiliximab: A bispecific nanobody targeting both PD-L1 and CD47. This novel immunotherapy is designed to target both the innate and adaptive immune systems, illustrating Shaperon's innovative approach in cancer treatment through dual-action mechanisms.
- Saviximab: A single domain neutralizing antibody aimed at SARS-CoV-2, demonstrating Shaperon’s agility in responding to emergent global health crises by offering potential solutions against novel pathogens.
- Undisclosed Nanobody Product Candidate: Currently under development for use in oncology. While specific details are not provided, this project hints at Shaperon’s ongoing commitment to expanding its portfolio in cancer therapeutics, exploring new avenues in nanobody technology.
Contact Information
Address: Gangnam Ace Tower G9
Phone: 82 2 6083 8315
Website: https://www.shaperon.com
